BIOASIS TECHNOLOGIES INC announced the addition of Mario Saltarelli, M.D., Ph.D., senior vice president of early development and neurology at Vertex Pharmaceuticals Incorporated, Jack Hoppin, Ph.D., co-founder and chief executive officer at Invicro, and Sue O’Connor, B.Sc. (Hons), Ph.D., vice president of neuroscience research at Bionomics, to its scientific advisory board (SAB). Dr. Mario Saltarelli is a senior vice president of early development and neurology at Vertex Pharmaceuticals Incorporated. Dr. Saltarelli leads Vertex’s early development activities, including translational medicine, clinical pharmacology, clinical biomarkers and neurology. For more than 20 years, Dr. Saltarelli has been focused on defining, building and successfully advancing development pipelines through the application of advanced translational paradigms in the biomedical and pharmaceutical sectors. Prior to joining Vertex, Dr. Saltarelli served as chief medical officer at Annexon Biosciences Inc. and served as the chief science officer and senior vice president of Mallinckrodt. Dr. Saltarelli served as senior vice president of clinical development and medical affairs at Shire. Dr. Jack Hoppin is the co-founder and chief executive officer of Invicro. Invicro, LLC was founded with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Dr. Hoppin served as the vice president of imaging systems at Bioscan Inc.Dr. Hoppin, a thought-leader in the molecular imaging research and drug development community, brings 15+ years in experience in the design, development and commercialization of pre-clinical instrumentation, analytical software and imaging-based assays. As an active member of the imaging community, Dr. Hoppin recently serving on the World Molecular Imaging Society Board of Trustees. He is also a member of the Society of Nuclear Medicine CMIIT Industry Council and the Harvard Catalyst Faculty. Dr. Sue O'Connor is currently vice president of neuroscience research at Bionomics Ltd. in Adelaide, Australia. Bionomics. Dr. O’Connor joined Bionomics in 2003 as a member of the drug discovery team before her appointment as senior director of central nervous system research and development. Her role at Bionomics has included a high level of involvement with the identification of BNC210. Dr. O’Connor’s current focus is the development of new drugs to treat cognitive impairment associated with several disease states.